Exploring new peptides for antibiotics and cancer treatments
Discovery and characterization of biocatalysts and metabolites for ribosomally encoded alpha-N-methylated peptide natural products
This study is exploring new types of natural compounds that could become better antibiotics and cancer treatments, aiming to help patients by making these medicines work more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11011646 on NIH RePORTER |
What this research studies
This research investigates the discovery and characterization of new bioactive peptides that are modified to enhance their effectiveness as antibiotics and anti-cancer agents. By focusing on peptides with specific structural features, such as α-N-methylation, the research aims to improve their pharmacokinetics, making them more effective in treating diseases. The approach includes identifying new metabolites from pathogens and understanding the mechanisms behind their production and function. Patients may benefit from the development of novel treatments derived from these peptides.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with conditions that may benefit from new antibiotic or anti-cancer therapies, particularly those resistant to current treatments.
Not a fit: Patients who do not have antibiotic-resistant infections or cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and more effective treatments for cancer and antibiotic-resistant infections.
How similar studies have performed: Previous research has shown promise in developing bioactive peptides as therapeutic agents, indicating that this approach has potential for success.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Freeman, Michael F — University of Minnesota
- Study coordinator: Freeman, Michael F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.